The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin

Diabetologia

Volumn 49, Issue 5, 2006, Pages 1064-1070

  Tooke, J E ^a   Elston, L M ^a   Gooding, K M ^a   Ball, C I ^a   Mawson, D M ^a   Piper, J ^a   Sriraman, R ^a   Urquhart, R ^b   Shore, A C ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b Takeda Global Research and Development Centre (Europe) Ltd   (United Kingdom)

Author keywords

Capillary filtration; Insulin sensitivity; Microcirculation; Oedema; Pioglitazone; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; INTERLEUKIN 6; METFORMIN; PIOGLITAZONE; PLACEBO; VASCULOTROPIN;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; CAPILLARY PERMEABILITY; CAPILLARY PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; MALE; MICROCIRCULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BLOOD VESSEL; VASOCONSTRICTION; VEIN OCCLUSION; VENOUS PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICROCIRCULATION; MIDDLE AGED; PLACEBOS; THIAZOLIDINEDIONES;

EID: 33646410110     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0168-9     Document Type: Article

References (36)

1. Lim SC, Caballero AE, Arora S et al (1999) The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes. J Clin Endocrinol Metab 84:4159-4164
2. Tsujimoto G (2000) Impaired coronary microvascular function in diabetics. Ann Nucl Med 14:165-172
3. Caballero AE, Arora S, Saouaf R et al (1999) Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48:1856-1862
4. Jaap AJ, Hammersley MS, Shore AC, Tooke JE (1994) Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 37:214-216
5. Jaap AJ, Shore AC, Tooke JE (1997) Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia 40:238-243
6. Wong TY, Klein R, Sharrett AR et al (2002) Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA 287:2528-2533
7. Tooke JE (2000) Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J Diabetes Complications 14:197-200
8. Tooke JE, Hannemann MM (2000) Adverse endothelial function and the insulin resistance syndrome. J Intern Med 247:425-431
9. Serne EH, Stehouwer CD, ter Maaten JC et al (1999) Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 99:896-902
10. Vincent MA, Clerk LH, Lindner JR et al (2004) Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 53:1418-1423
11. Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark AD, Clark MG (2002) Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats. Diabetes 51:3492-3498
12. Vasudevan AR, Balasubramanyam A (2004) Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 6:850-863
13. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S (2002) Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 56:251-257
14. Mudaliar S, Chang AR, Henry RR (2003) Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 9:406-416
15. Fahr G, Ershler I (1941) Studies of the factors concerned in edema formation. II The hydrostatic pressure in the capillaries during edema formation in right heart failure. Ann Intern Med 15:798-810
16. Williams SA, Rayman G, Tooke JE (1989) Dependent oedema and attenuation of postural vasoconstriction associated with nifedipine therapy for hypertension in diabetic patients. Eur J Clin Pharmacol 37:333-335
17. Lewis DM, Tooke JE, Beaman M, Gamble J, Shore AC (1998) Peripheral microvascular parameters in the nephrotic syndrome. Kidney Int 54:1261-1266
18. Hassan AA, Carter G, Tooke JE (1990) Postural vasoconstriction in women during the normal menstrual cycle. Clin Sci (Lond) 78:39-47
19. Mahy IR, Shore AC, Smith LD, Tooke JE (1995) Disturbance of peripheral microvascular function in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Cardiovasc Res 30:939-944
20. Hassan AA, Tooke JE (1988) Mechanism of the postural vasoconstrictor response in the human foot. Clin Sci (Lond) 75:379-387
21. Nakamura Y, Ohya Y, Onaka U, Fujii K, Abe I, Fujishima M (1998) Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol 123:675-682
22. Niemeyer NV, Janney LM (2002) Thiazolidinedione-induced edema. Pharmacotherapy 22:924-929
23. Bando Y, Ushiogi Y, Okafuji K, Toya D, Tanaka N, Fujisawa M (1999) Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors. J Int Med Res 27:53-64
24. Saad MF, Greco S, Osei K et al (2004) Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 27:1324-1329
25. Christ F, Bauer A, Brugger D, Niklas M, Gartside IB, Gamble J (2000) Description and validation of a novel liquid metal-free device for venous congestion plethysmography. J Appl Physiol 89:1577-1583
26. Gamble J, Christ F, Gartside IB (1998) Human calf precapillary resistance decreases in response to small cumulative increases in venous congestion pressure. J Physiol 507:611-617
27. Shore AC, Price KJ, Sandeman DD, Tripp JH, Tooke JE (1994) Posturally induced vasoconstriction in diabetes mellitus. Arch Dis Child 70:22-26
28. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684
29. Mohanty P, Aljada A, Ghanim H et al (2004) Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89:2728-2735
30. Satoh N, Ogawa Y, Usui T et al (2003) Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26:2493-2499
31. Baba T, Shimada K, Neugebauer S, Yamada D, Hashimoto S, Watanabe T (2001) The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care 24:953-954
32. Jaap AJ, Pym CA, Seamark C, Shore AC, Tooke JE (1995) Microvascular function in type 2 (non-insulin-dependent) diabetes: improved vasodilation after one year of good glycaemic control. Diabet Med 12:1086-1091
33. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
34. Scheen AJ (2004) Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf 27:841-856
35. Marceille JR, Goins JA, Soni R, Biery JC, Lee TA (2004) Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Pharmacotherapy 24:1317-1322
36. Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M (2004) Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract 58:833-837